TABLE 4.
Analysis of incidence of CHD death or nonfatal MI on trial by SNP carrier status: new cases/total subjects (597/5,418)
| Adjusteda | Placebob | Pravastatinb | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | Number of New Cases/ Total Subjects (%) | HRc | P | Number of new case/ Total subjects (%) | HRc | P | Number of new case/ Total subjects (%) | HRc | P | |
| −133 A>G | AA + AG | 534/4819 (11.1) | 1 | 0.99 | 291/2429 (12.0) | 1 | 0.8 | 243/2390 (10.2) | 1 | 0.8 |
| GG | 63/573 (11.0) | 1.00 (0.77-1.30) | 35/291 (12.0) | 1.04 (0.73-1.48) | 28/282 (9.9) | 0.96 (0.65-1.42) | ||||
| −18 A>C | AA +AC | 574/5272 (10.9) | 1 | 0.04 | 314/2658 (11.8) | 1 | 0.2 | 260/2614 (9.9) | 1 | 0.06 |
| CC | 23/126 (18.3) | 1.67 (1.10-2.54) | 12/67 (17.9) | 1.51 (0.84-2.69) | 11/59 (18.6) | 1.78 (0.97-3.27) | ||||
| L272L | CC + CG | 557/5136 (10.8) | 1 | 0.04 | 301/2587 (11.6) | 1 | 0.05 | 256/2549 (10.0) | 1 | 0.5 |
| GG | 41/259 (15.8) | 1.50 (1.09-2.06) | 26/136 (19.1) | 1.66 (1.11-2.49) | 15/123 (12.2) | 1.23 (0.73-2.06) | ||||
| V1296V | CC + CT | 561/5178 (10.8) | 1 | 0.03 | 306/2602 (11.8) | 1 | 0.1 | 255/2576 (9.9) | 1 | 0.05 |
| TT | 36/216 (16.7) | 1.56 (1.11-2.18) | 21/120 (17.5) | 1.46 (0.94-2.27) | 15/96 (15.6) | 1.68 (0.99-2.83) | ||||
| U3_28650 A>G | AA + AG | 562/5178 (10.9) | 1 | 0.04 | 305/2599 (11.7) | 1 | 0.1 | 257/2579 (10.0) | 1 | 0.1 |
| GG | 35/217 (16.1) | 1.50 (1.07-2.11) | 21/122 (17.2) | 1.43 (0.92-2.23) | 14/95 (14.7) | 1.58 (0.92-2.71) |
a
P values for men and women combined; adjusted for gender, body mass index, age, alcohol, smoking, diabetes, hypertension, apoE phenotype, randomized treatment, and country. No significant differences were noted when men and women were separated.
b
P values for men and women combined; adjusted for gender, body mass index, age, alcohol, smoking, diabetes, hypertension, apoE phenotype, and country. No significant differences were noted when men and women were separated.
c
Hazards ratio (95% confidence intervals).